Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Successful Therapy of a Patient with a Novel STAT1 Gain of Function Mutation and Life-Threatening Cytopenias with Janus Kinase Inhibitor Ruxolitinib

Katja G. Weinacht, MD PhD, Louis m Charbonnier, PhD, Ashley Plant, MD, Troy Torgerson, MD PhD, Sergei Rosenzweig, MD PhD, Thomas Fleisher, MD PhD, Luigi Daniele Notarangelo, MD

Blood (2015) 126 (23): 3434.

https://doi.org/10.1182/blood.V126.23.3434.3434

Published: 2015

Journal Articles

Somatic Fas Mutations Account for Nearly One Third of Autoimmune Lymphoproliferative Syndrome (ALPS) Cases with Previously Unknown Genetic Mutations.

Kennichi Dowdell, PhD, Julie Niemela, Susan Price, Joie Davis, Katie Perkins, Janet Dale, Jennifer M. Puck, MD, Joao Bosco Oliveira, MD, PhD, Jeffrey Cohen, MD, Thomas Fleisher, MD, V. Koneti Rao, MD

Blood (2009) 114 (22): 710.

https://doi.org/10.1182/blood.V114.22.710.710

Published: 2009

Journal Articles

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Janet K. Dale, RN, Susan Price, RN, Jean Tretler, RN, Patricia Aldridge, RN, Stephanie Montague, RN MSN, Joie Davis, APRN, Fred Gill, MD, Kip R. Hartman, MD, Linda C. Stork, MD, David J. Gnarra, MD, Lakshmanan Krishnamurti, MD, Jennifer Puck, MD, Thomas Fleisher, MD, V. Koneti Rao, MD

Blood (2007) 110 (11): 1319.

https://doi.org/10.1182/blood.V110.11.1319.1319

Published: 2007

Journal Articles

Role of Somatic Fas Mutations in the Pathogenesis of Autoimmune Lymphoproliferative Syndrome (ALPS).

Kennichi C. Dowdell, PhD, Julie Niemela, BS, MT(ASCP), Janet K. Dale, RN, MPH, Jennifer Puck, MD, V. Koneti Rao, MD, Thomas Fleisher, MD, Stephen E. Straus, MD

Blood (2006) 108 (11): 3900.

https://doi.org/10.1182/blood.V108.11.3900.3900

Published: 2006

Journal Articles

IL7 Administration in Humans Results in Preferential Expansion of Naive and Memory CD4+ & CD8+ T Cells with a Relative Decrease in Regulatory T-Cells (T-Regs).

Claude Sportes, MD, Michael Krumlauf, RN, Rebecca Babb, RN, Ladan Foruraghi, RN, Janine Daub, RN, Daniele Avila, RN, Catherine Chow, MD, Hua Zhang, PhD, Kevin Chua, PhD, Terry Fry, MD, Sarfraz Memon, PhD, Frances Hakim, PhD, Thomas Fleisher, MD, Margaret Brown, BSN, Julie Engel, PhD, Renaud Buffet, MD, Michel Morre, DVM, Ronald Gress, MD, Crystal Mackall, MD

Blood (2006) 108 (11): 871.

https://doi.org/10.1182/blood.V108.11.871.871

Published: 2006

NARROW

Successful Therapy of a Patient with a Novel STAT1 Gain of Function Mutation and Life-Threatening Cytopenias with Janus Kinase Inhibitor Ruxolitinib

Somatic Fas Mutations Account for Nearly One Third of Autoimmune Lymphoproliferative Syndrome (ALPS) Cases with Previously Unknown Genetic Mutations.

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Role of Somatic Fas Mutations in the Pathogenesis of Autoimmune Lymphoproliferative Syndrome (ALPS).

IL7 Administration in Humans Results in Preferential Expansion of Naive and Memory CD4+ & CD8+ T Cells with a Relative Decrease in Regulatory T-Cells (T-Regs).

Email alerts

ASH Publications

American Society of Hematology

Successful Therapy of a Patient with a Novel STAT1 Gain of Function Mutation and Life-Threatening Cytopenias with Janus Kinase Inhibitor Ruxolitinib

Somatic Fas Mutations Account for Nearly One Third of Autoimmune Lymphoproliferative Syndrome (ALPS) Cases with Previously Unknown Genetic Mutations.

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Role of Somatic Fas Mutations in the Pathogenesis of Autoimmune Lymphoproliferative Syndrome (ALPS).

IL7 Administration in Humans Results in Preferential Expansion of Naive and Memory CD4+ & CD8+ T Cells with a Relative Decrease in Regulatory T-Cells (T-Regs).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only